List view / Grid view
Dupixent® is the first biologic to demonstrate significant improvement in…
Dupixent® is the first biologic to demonstrate significant improvement in lung function compared to placebo, a pivotal Phase III trial has shown.
Dupixent®, the first and only targeted medicine for prurigo nodularis…
Dupixent®, the first and only targeted medicine for prurigo nodularis has been approved by the EC for adults with a moderate-to-severe form of the condition.
Sanofi and Regeneron Pharmaceuticals, Inc. have announced that the EC…
Sanofi and Regeneron Pharmaceuticals, Inc. have announced that the EC has granted marketing authorisation for Dupixent for use in adults with moderate-to-severe atopic dermatitis...
